Abstract
BackgroundSTING activates Type1 interferon and pro-inflammatory responses to drive anti-tumor immunity. Current STING agonists under clinical investigation show limited efficacy due to safety considerations that prevent systemic administration. CRD3874-SI, a...
Full Text
Sign-in/Register to access full text options
Published version (Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have